Biology Insights

What It Means When Lymphovascular Invasion Is Present

Deciphering a common pathology finding: understand its implications for cancer’s behavior and how it informs your medical care.

By Meredith Wallace

Lymphovascular invasion (LVI) on a pathology report means that cancer cells have been found inside blood vessels, lymphatic vessels, or both within or near the tumor. It is a sign that cancer has begun the process of spreading beyond the primary tumor site, even if it has not yet reached the lymph nodes or distant organs. LVI is one of several features pathologists look for under the microscope, and its presence generally shifts a tumor into a higher-risk category, though the practical consequences depend heavily on the cancer type, stage, and other pathological findings.

What a Pathologist Actually Sees

When a tumor is removed surgically or sampled through biopsy, the tissue is sliced, stained, and examined under a microscope. Pathologists look for clusters of tumor cells sitting inside vessel-shaped spaces in the tissue. Sometimes the invasion is obvious: a clump of cancer cells floating inside a clearly defined vessel lined by endothelial cells. Other times, the picture is far less clear. Tissue processing can create shrinkage gaps around tumor nests that look almost identical to vessel spaces. These “retraction artifacts” are one of the most common sources of confusion in LVI assessment. In endometrial cancer pathology, this problem is common enough that mimics are given their own name: pseudo-LVSI.

Standard tissue staining (the classic hematoxylin and eosin, or H&E) can miss a significant number of invasion events. Special immunohistochemical stains that highlight vessel walls have been shown to pick up more LVI than H&E alone, and they can distinguish between blood vessel invasion and lymphatic vessel invasion. Whether a lab uses these additional stains depends on the institution, the cancer type, and the clinical question being asked. In everyday practice, most initial assessments still rely on H&E, with immunohistochemistry reserved for borderline or clinically important cases.

Why It Matters for Prognosis

The core reason oncologists care about LVI is that it signals a higher likelihood of recurrence and, in many cancers, worse survival. A tumor that has already entered vessels has crossed an important biological threshold: it has gained access to the body’s highway system. That does not guarantee it will establish colonies elsewhere, but it means the machinery for doing so is already in play. Across a wide range of cancer types, LVI consistently shows up as an independent risk factor, meaning it adds prognostic information even after accounting for tumor size, grade, and lymph node involvement.

In breast cancer, this relationship is especially well studied. One large analysis found that in patients whose lymph nodes were negative, LVI carried a survival disadvantage roughly equivalent to having one or two positive lymph nodes. That is a meaningful jump in risk for a feature found within the primary tumor itself. A separate study of invasive breast cancers found that patients with LVI had roughly triple the risk of disease recurrence and about two-and-a-half times the risk of death compared with those without it. After adjusting for other factors, LVI remained an independent predictor of both outcomes.

Colorectal and Gastric Cancers

LVI is one of the most clinically actionable findings in colorectal cancer, particularly in stage II disease. Stage II means the tumor has grown through the bowel wall but has not reached the lymph nodes. The default for many stage II patients is surgery alone, without chemotherapy. But when LVI is present, a meta-analysis found that it roughly doubled the risk of death and increased the risk of recurrence by about 70%, shifting those patients into a category where chemotherapy is strongly considered. A separate study confirmed that LVI is an independent prognostic risk factor in stage II colorectal cancer and that adjuvant chemotherapy benefits survival in LVI-positive patients. Venous invasion in particular has been flagged as a high-degree risk factor that may warrant chemotherapy in stage II disease.

In gastric cancer, LVI similarly upgrades risk. For early-stage tumors that might initially appear amenable to endoscopic removal (a less invasive procedure that avoids major surgery), the discovery of LVI in the specimen is a reason to consider full surgical resection instead. Research has shown that LVI in early gastric cancers is associated with a higher rate of lymph node involvement and metastatic spread, making the less aggressive approach insufficient for tumor control. For node-negative gastric cancers, adding LVI to the standard staging system improves the accuracy of predicting outcomes.

A study of node-negative gastric cancer patients found that those with LVI-positive tumors at a certain depth of invasion had survival outcomes comparable to patients with positive lymph nodes, a full stage higher. In other words, LVI effectively erased the survival advantage of having clean lymph nodes.

Prostate and Bladder Cancers

In prostate cancer, LVI is found less often than in some other malignancies, but when present it carries a clear signal. A systematic review and meta-analysis found that LVI is associated with nearly double the risk of biochemical recurrence after radical prostatectomy. An earlier systematic review that examined the question across 19 studies found that the majority concluded LVI was an independent predictor of recurrence, with the magnitude of the association ranging widely depending on the study population.

In bladder cancer, LVI is especially concerning because it correlates with the risk that the cancer’s true stage is worse than what the initial biopsy suggested. A meta-analysis found that the presence of LVI at the time of transurethral resection portends an increased risk of pathologic upstaging, meaning a tumor initially classified as non-muscle-invasive may turn out to invade deeper than first thought. In one study, LVI was among the strongest predictors of cancer-specific death, with patients who had LVI at initial resection faring significantly worse than those without it.

Melanoma and Skin Cancers

LVI in melanoma has a more nuanced relationship with outcomes. In one study using immunohistochemical staining, LVI was detected in about a quarter of invasive melanomas. Those patients were far more likely to have a positive sentinel lymph node biopsy: roughly two-thirds of patients with LVI had a positive node, compared with fewer than one in five without LVI. A separate study confirmed the link to sentinel node positivity but found that LVI was not an independent predictor of overall survival in the general melanoma population after adjusting for other factors like tumor thickness and ulceration. However, among patients whose tumors showed regression (a specific histological feature), LVI was a powerful predictor: the five-year survival rate was about 49% with LVI versus 81% without it.

For cutaneous squamous cell carcinoma, both major clinical guideline systems recognize various high-risk features that influence staging and treatment planning, and LVI is considered among them.

Lymphatic Invasion Versus Blood Vessel Invasion

Most pathology reports group both types together under the umbrella term “lymphovascular invasion,” but they are not identical. Lymphatic invasion means tumor cells have entered the lymphatic vessels, which drain toward regional lymph nodes. Blood vessel (vascular) invasion means tumor cells have entered the blood vasculature, which connects to distant organs. The biological implications overlap but are not the same, and a growing number of studies have tried to tease them apart.

A meta-analysis of esophageal squamous cell carcinoma found that both lymphatic invasion and vascular invasion predicted worse overall survival. However, lymphatic invasion was a better predictor of recurrence-free survival, while vascular invasion’s association with recurrence did not reach statistical significance. In early-stage endometrial cancer, a study compared outcomes among patients with lymphatic invasion alone, vascular invasion alone, or both, and found no statistically significant differences among the three groups for overall survival or distant spread. The practical takeaway is that while researchers are working to differentiate the two, the overall presence of either type still signals elevated risk, and routine pathology reporting at most institutions does not always distinguish between them.

How LVI Changes Treatment Decisions

The main way LVI affects your care is by pushing treatment toward the more aggressive end of the spectrum. In cancers that are otherwise early stage and might not automatically receive chemotherapy or radiation, LVI can tip the balance. This plays out differently depending on the cancer type:

In endometrial cancer, LVI is recognized as an independent risk factor for both nodal metastasis and distant recurrence, influencing decisions about whether adjuvant radiation or chemotherapy should be offered. These decisions are made in multidisciplinary team discussions, weighing LVI alongside other risk factors to tailor a plan for each patient rather than applying a blanket rule.

The Biology Behind Vessel Invasion

Tumors do not simply fall into blood and lymphatic vessels by accident. The process involves active biological steps. Tumor cells must detach from the primary mass, move through surrounding tissue, and then breach the walls of vessels. One of the key biological programs involved is a shift in cell behavior where epithelial cells, which normally stay tightly connected to their neighbors, acquire traits of mesenchymal cells, which are mobile and invasive. This transition enables tumor cells to move as individuals or small groups, penetrate surrounding tissue, and enter vessels. In animal models, cells that had undergone this transition were found inside blood vessels and in the bloodstream, while cells that had not made the shift could not enter the vasculature at all.

On the lymphatic side, tumors can actively promote the growth of new lymphatic vessels around and within themselves. They do this by secreting signaling proteins, particularly VEGF-C and VEGF-D, which stimulate lymphatic vessel formation. In gastric cancer, the expression of these proteins correlates with lymphatic invasion, lymph node metastasis, and in some cases reduced survival. Similar findings have been reported in lung cancer, where these same growth factors promote lymphatic vessel formation and facilitate spread to the lymphatic system. In other words, many tumors don’t just passively leak into nearby vessels. They actively remodel their surroundings to create new routes for escape.

Why Different Pathologists Sometimes Disagree

One of the less-discussed realities of LVI is that pathologists do not always agree on whether it is present. Borderline cases, where tissue shrinkage mimics vessel invasion or where only one or two suspicious foci are seen, are genuinely difficult to call. In breast cancer, a study of diagnostic agreement found that concordance was highest when LVI was clearly absent or when multiple involved vessels were seen, but it was more variable in ambiguous cases.

In colorectal cancer, agreement among pathologists for small vessel invasion on H&E staining was only fair, and agreement for large vessel invasion was even worse. Adding immunohistochemical stains did not substantially improve agreement. In endometrial cancer, a study of gynecologic pathologists found moderate agreement on whether LVI was present, with perfect agreement only occurring when all reviewers agreed there was no LVI at all or when five or more involved vessels were visible.

This variability matters because treatment decisions can hinge on the finding. If you receive a pathology report that calls LVI “equivocal” or “suspicious,” asking whether immunohistochemical staining was performed or whether a second opinion is warranted can be a reasonable step, particularly if the finding would change your treatment plan.

Artificial Intelligence in LVI Detection

Given the subjectivity involved in identifying LVI, there has been growing interest in using artificial intelligence to assist pathologists. Several research groups have developed deep learning models that analyze digitized tissue slides and flag regions suspicious for LVI. A study in lung adenocarcinoma developed a two-step model that first identifies blood vessels in the tissue, then classifies whether LVI is present. The system achieved very high accuracy and, in a pilot study, reduced the time pathologists spent evaluating LVI by an average of about 17%, and by more than 20% in difficult cases. Similar work has been explored in testicular cancer.

A broader review of the field noted that AI and digital pathology tools also hold promise for predicting LVI preoperatively, using biopsy samples or even MRI imaging, which could help guide surgical planning before the tumor is removed. These tools are still in the research phase at most institutions, but they point toward a future where LVI detection is more consistent and less dependent on the individual pathologist’s judgment.

LVI and the Immune Landscape

An emerging area of research links LVI to the tumor’s immune environment in ways that could eventually influence treatment with immunotherapy. In resected lung cancers, LVI was associated with higher tumor mutational burden and higher PD-L1 expression, two markers that are used to select patients for immune checkpoint inhibitors. Tumors that had LVI were roughly three-and-a-half times more likely to have both elevated mutational burden and PD-L1 expression simultaneously. This does not mean LVI-positive tumors are candidates for immunotherapy as a rule, but it raises the possibility that the biology underlying vessel invasion overlaps with the features that make some tumors responsive to immune-based treatments. As immunotherapy expands into more cancer types and settings, understanding whether LVI-positive tumors have distinct immune profiles could shape future treatment strategies.

Related Content

More in Cancer